CTC Bio

CTC Bio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of CTC Bio (060590.KQ) as of Oct 28, 2026 is 106.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -45.15 % — a change of -336.37% (higher).

FCF Conversion

106.72 %

YoY

-336.37%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of CTC Bio is 2025 106.72 % . FCF Conversion Rate (FCF/EBITDA) of CTC Bio was 2024 -45.15 % . It decreases by -336.37% higher compared to the previous year.

The CTC Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
43.83 KRW
Jan 1, 2019
3.93 KRW
Jan 1, 2020
7.27 KRW
Jan 1, 2021
-65.36 KRW
Jan 1, 2022
222.92 KRW
Jan 1, 2023
-40.62 KRW
Jan 1, 2024
-45.15 KRW
Jan 1, 2025
106.72 KRW
The CTC Bio FCF Conversion history
YEARFCF ConversionYoY
106.72 %-336.37%
-45.15 %+11.16%
-40.62 %-118.22%
222.92 %-441.05%
-65.36 %-999.49%
7.27 %+84.88%
3.93 %-91.03%
43.83 %+151.41%
17.43 %-92.76%
240.92 %-129.64%
-812.75 %-201.05%
804.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

FCF Conversion Rate (FCF/EBITDA) of CTC Bio is 106.72 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of CTC Bio changed from -45.15 % to 106.72 %, representing a -336.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) CTC Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s CTC Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CTC Bio

All Key Metrics — CTC Bio